Entities / Company
Immutep.
Biotechnology company
- Reports this week
- 0
- Active events
- 1
- Connections
- 28
What's happening
Active this week
Gone quiet
No new reports in 90+ days-
Immutep violated securities laws monitored by SEC.Some support3 reports1 development inside
-
Immutep filed a Form-K with the SEC on June 1, 2026.Some support1 report
-
Immutep, a company based in Los Angeles, is facing charges related to market disclosures.Some support1 report
-
A law firm is handling a class action lawsuit against Immutep.Some support1 report1 development inside
-
Nathan Miller is identified as the Client Relations Manager.Some support1 report
-
Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.Some support1 report
-
Immutep appointed Frédéric Triebel as its Chief Scientific Officer.Speculative1 report
-
Immutep is developing novel immunotherapies for autoimmune diseases using IMP761, which functions as a LAG-3 agonist antibody.Speculative1 report
-
Immutep accepted abstracts for presentation at the ESMO Congress 2025, which was held in Berlin.Some support1 report
-
Immutep's clinical trial utilized MSD's anti-PD-1 drug, and the FDA provided positive feedback regarding the potential for treatment development.Some support2 reports1 development inside
-
Immutep reports activities from Sydney, Australia.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Immutep this week
News at the entities that move Immutep most-
MSD StructuralMSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Moves Immutep
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Immutep
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Immutep
-
company StructuralBoard approved a quarterly cash dividend increase on August 1, 2026.Moves Immutep
-
Los Angeles Shared contextLos Angeles City Council voted to allow noncitizen voting in city elections, supported by Angelica Salas.Moves Immutep
-
New York City Shared contextJoint entities are driving a high volume of General Obligation bond issuance in New York City.Moves Immutep
Connections
The 8 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nathan Miller Structural
Nathan Miller is employed by Immutep as a Client Relations Manager.
-
Frédéric Triebel Structural
Frédéric Triebel serves as the Chief Scientific Officer (CSO) of Immutep.
-
MSD Structural
Immutep utilizes MSD's anti-PD-1 therapy and drugs in its clinical trials and operations.
-
FDA Structural
FDA provides regulatory feedback and approval for Immutep's clinical development and treatment potential.
-
SEC Structural
Immutep is subject to the oversight and regulatory enforcement actions of the SEC regarding securities laws and market disclosures.
-
company Structural
Immutep operates within the market structure and regulatory environment of the larger corporate entity, facing securities fraud concerns.
-
Los Angeles Shared context
Immutep is headquartered in Los Angeles, California.
-
New York City Shared context
Immutep was involved in a lawsuit filed within New York City.
History
Events by the month they beganJune 2026
12 events- A lawsuit was filed against the company Immutep in New York City.
- Immutep violated securities laws monitored by SEC.
- Immutep filed a Form-K with the SEC on June 1, 2026.
- Immutep, a company based in Los Angeles, is facing charges related to market disclosures.
- A law firm is handling a class action lawsuit against Immutep.
- Nathan Miller is identified as the Client Relations Manager.
- Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.
- Immutep appointed Frédéric Triebel as its Chief Scientific Officer.
- Immutep is developing novel immunotherapies for autoimmune diseases using IMP761, which functions as a LAG-3 agonist antibody.
- Immutep accepted abstracts for presentation at the ESMO Congress 2025, which was held in Berlin.
- Immutep's clinical trial utilized MSD's anti-PD-1 drug, and the FDA provided positive feedback regarding the potential for treatment development.
- Immutep reports activities from Sydney, Australia.